Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

The Iseq All-Share index fell almost 1 per cent to 11,143.28. Ryanair stood out as a weak spot, sliding 2.1 per cent as ...

The UK's FTSE 100 extended its winning streak to a fourth week on Friday, as investors looked past economic concerns to focus ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

As of June 30, the Fund held 46.2% in U.S. equities, 17.9% in non-U.S. equities, and 35.9% in fixed income securities plus ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

After strong multi-year performance in Financials, Dodge & Cox Global Stock Fund continued to steadily reduce its overweight position in the sector. Read more here.